Outpatient Treatment of PE and DVT in the Emergency Department

March 5, 2019 updated by: Christopher Kabrhel, Massachusetts General Hospital

Outpatient Treatment of Pulmonary Embolism and Deep Vein Thrombosis: Impact of a New Protocol on Emergency Department Efficiency and Patient Safety

Standardize the approach to outpatient Pulmonary Embolism (PE) and Deep Vein Thrombosis (DVT) treatment.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

In the current protocol, we will study the outcomes most likely to influence emergency physician behavior, such as improved Emergency Department (ED) throughput, and decreased ED and Emergency Department Observation Unit (EDOU) length of stay. Metrics such as decreased admissions are also very important to hospital administrators so our results will have impact outside the ED as well. At the end of this study we will demonstrate that a carefully planned and data-driven approach to the outpatient treatment of Pulmonary Embolism (PE) is safe, improves operational metrics, and reduces cost.

Study Type

Observational

Enrollment (Actual)

400

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Massachusetts
      • Boston, Massachusetts, United States, 02115
        • Brigham and Women's Hospital
      • Boston, Massachusetts, United States, 02114
        • Massachusetts General Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

This is a multi-center prospective, observational study of MGH or BWH patients with PE or DVTwith historical and contemporary controls.

Description

Inclusion Criteria:

  • Subject is 18 years of age or older at time of enrollment.
  • Subject is diagnosed with acute VTE (DVT or PE) in the MGH or BWH ED or transferred to the MGH or BWH ED (e.g from a clinic or outside hospital) with a diagnosis of acute VTE.
  • Subject is treated as an outpatient (i.e. discharged) directly from the ED or admitted to the ED Observation Unit/ED Short Stay Unit on the outpatient treatment protocol.

Exclusion Criteria:

  • Subjects admitted from the ED to an inpatient service will not be enrolled as study subjects, but will be used as contemporary controls.
  • Subjects who are unable to understand or provide informed consent.
  • Subjects unable or unlikely to follow up (e.g. prisoners).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
MGH ED/EDOU patients

Subjects who present to the Massachusetts General Hospital (MGH) ED or EDOU who meet all inclusion and no exclusion criteria.

Intervention: Telephone follow-up at 7 and 30 days.

Prospectively enrolled subjects will have a 7- and 30-day phone call.
BWH ED/EDOU patients

Subjects who present to the Brigham and Women's Hospital (BWH) ED or EDOU who meet all inclusion and no exclusion criteria.

Intervention: Telephone follow-up at 7 and 30 days.

Prospectively enrolled subjects will have a 7- and 30-day phone call.
Control subjects
  1. Contemporary controls: subjects diagnosed with Venous Thromboembolism (VTE) in the ED and who are not eligible for outpatient treatment
  2. Historical controls:

    1. Subjects enrolled in the prospective and retrospective SPEED-D study (PI: Kabrhel) and diagnosed with PE between 2006-2012.
    2. Subjects diagnosed with VTE in the MGH and BWH ED in the 18 months prior to the use of the clinical outpatient treatment of PE protocol.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Efficiency & cost of clinical protocol
Time Frame: Up to 30 days

To compare patients diagnosed with VTE after protocol implementation to those diagnosed with VTE prior to protocol implementation in terms of four measures of efficiency:

A) ED length of stay - defined as time from ED registration to departure from the ED (to either the inpatient floor or to the EDOU).

B) ED disposition time - defined as time from ED registration to bed request.

C) Hospital length of stay - defined as time from ED registration to departure from the hospital.

D) Cost - defined as the estimated cost of care including diagnostic testing, imaging, hospital inpatient/observation unit stay, medication/pharmacy costs.

Up to 30 days
Safety of clinical protocol
Time Frame: Up to 30 days

To assess the safety of outpatient VTE treatment, specifically with regards to:

A) recurrent venous thromboembolism;

B) bleeding (major or minor);

C) unscheduled return to hospital for any reason;

D) death from any cause: occurring up to 30 days after their discharge.

Up to 30 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Christopher Kabrhel, MD MPH, Massachusetts General Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 1, 2015

Primary Completion (Actual)

February 1, 2017

Study Completion (Actual)

February 1, 2017

Study Registration Dates

First Submitted

August 20, 2015

First Submitted That Met QC Criteria

August 24, 2015

First Posted (Estimate)

August 25, 2015

Study Record Updates

Last Update Posted (Actual)

March 6, 2019

Last Update Submitted That Met QC Criteria

March 5, 2019

Last Verified

March 1, 2019

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Deep Vein Thrombosis

Clinical Trials on Telephone follow-up

Subscribe